By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eli Lilly and Company 

Lilly Corporate Center

Indianapolis  Indiana  46285  U.S.A.
Phone: 317-276-2000 Fax: n/a


Lilly makes medicines that help people live longer, healthier, more active lives. We were founded by Eli Lilly in 1876, and are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Lilly is consistently ranked as one of the best companies in the world to work for, and generations of Lilly employees have sustained a culture that values excellence, integrity, and respect for people. Lilly's global employees number approximately 40,000, and our medicines are marketed in 143 countries. Lilly has major research and development facilities in eight countries and conducts clinical trials in more than 50 countries.

Making medicines has never been easy. But in today's global health care environment, the challenges are unprecedented. Familiar ways of working aren't working anymore, so Lilly is transforming to meet the challenges head on — from how we make medicines to how we talk about them. Throughout our organization, we're asking tough questions and discovering better answers.

Around the world people are in need of health care. People with medical needs above and beyond the capabilities of existing medicine. It is here, at the edge of science and medicine that Lilly begins. Lilly has embraced a bold vision. We intend to make a significant contribution to humanity by improving global health in the 21st century. Starting with the work of our scientists, we will place improved outcomes for individual patients at the center of what we do. We will listen carefully to understand patient needs and work with health care partners to provide meaningful benefits for the people who depend on us.

Lilly, a leading innovation driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers through medicines and information for some of the world’s most urgent medical needs.




CEO: John C. Lechleiter, PhD

CFO: Derica W. Rice


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Eli Lilly
Employees: 41,500 globally
Symbol: LLY


SLIL Biomedical Corporation  Worldwide licensing agreement with the animal health division for more than 40 compounds that have shown activity in animal infectious diseases.

Emisphere  Osteoporosis; Growth disorders

PanVera LLC 

Medarex, Inc. 


Daiichi Sankyo, Inc. 

Dyax  Antibody phage display

Company News
Eli Lilly (LLY) Heads to Finish Line with Breast Cancer Treatment Abemaciclib 9/19/2017 5:58:57 AM
Eli Lilly (LLY) Release: Baricitinib Meets Primary Endpoint In Phase II Study Of Patients With Moderate-To-Severe Atopic Dermatitis 9/14/2017 10:50:13 AM
Eli Lilly (LLY) To Present New Data For Olumiant (Baricitinib) And Taltz (Ixekizumab) At The European Academy Of Dermatology And Venereology (EADV) Annual Congress 9/13/2017 10:05:01 AM
Eli Lilly (LLY) Release: Jardiance (Empagliflozin) Tablets Reduced Risk Of Cardiovascular Death In People With Type 2 Diabetes And Established Cardiovascular Disease Independent Of Background Blood Sugar Control 9/12/2017 6:53:52 AM
IHC 2017: Eli Lilly (LLY)'s Lasmiditan Significantly Reduces Pain In Patients With Migraine 9/11/2017 10:41:12 AM
Eli Lilly (LLY) Builds Upon Body Of Clinical Evidence For CYRAMZA (Ramucirumab) With Phase III RANGE Data Demonstrating Superior Progression-Free Survival In Advanced Or Metastatic Urothelial Cancer 9/11/2017 8:44:46 AM
Eli Lilly (LLY) Chops 3,500 Jobs, Shuts Down 2 R&D Sites 9/7/2017 8:33:58 AM
Acrux (ACR) Plunges After Deal With Eli Lilly (LLY) Is Terminated 9/6/2017 5:45:59 AM
Rejected Only A Few Weeks Ago, Eli Lilly (LLY) Will Resubmit NDA App For Potential RA Blockbuster In Just 5 Months 8/30/2017 5:33:35 AM
Ophirex Licenses Eli Lilly (LLY)-Shionogi Data For Novel Snakebite Treatment Development Program 8/29/2017 9:05:01 AM